The global Retinal Biologics market, valued at $XX Million in 2020, is projected to reach $XX Million by 2028, expanding at a compound annual growth rate (CAGR) of 6.5% from 2021 to 2028. This growth is driven by various macroeconomic and microeconomic factors, notably the increasing prevalence of diseases such as age-related macular degeneration (AMD), which significantly fuels the demand for retinal biologics.
The latest research report by Evolve Business Intelligence explores the various factors influencing the global market. It includes an analysis of the current market size, forecasts for key segments and regions, and the driving forces behind market growth. The report examines the potential impacts of key trends on business strategies and provides a SWOT analysis of critical sectors for each major competitor and customer group. This valuable data highlights the conglomerates likely to impact the industry, crucial for any company planning to invest strategically over the next five years. These insights complement our initial quantitative study, aiding in new investments and strategic planning to mitigate threats in existing sectors.
Segments covered
By Drug Class (TNF-α Inhibitor, VEGF-A Antagonist)
By Retinal Disorder Type (Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Macular Hole, Uveitis, Others)
By Distribution Channel (Hospitals, Retail Pharmacies, Specialty Ophthalmology Clinics)
Key players
Novartis AG
Hoffmann La Roche Ltd
AbbVie Inc.
MeiraGTx Limited
OncoGene
Johnson & Johnson
Allergan
Bristol-Myers Squibb Company
Regeneron
Oxurion NV
- Chapter 1. Executive Summary
- Chapter 2. Scope of The Study
- 2.1. Market Definition
- 2.2. Scope of The Study
- 2.2.1. Objectives of Report
- Chapter 3. Evolve BI Methodology
- Chapter 4. Market Insights and Trends
- 4.1. Supply/ Value Chain Analysis
- 4.2. Porter’s Five Forces Analysis
- 4.2.1. Threat of New Entrants
- 4.2.2. Bargaining Power of Buyers
- 4.2.3. Bargaining Power of Suppliers
- 4.2.4. Threat of Substitutes
- 4.2.5. Industry Rivalry
- 4.3. Impact of COVID-19 on Retinal Biologics Market
- 4.3.1. Impact on Market Size
- 4.3.2. End User Trend, Preferences and Budget Impact
- 4.3.3. Regulatory Framework/Government Policies
- 4.3.4. Key Players Strategy to Tackle Negative Impact
- 4.3.5. Opportunity Window
- Chapter 5. Market Dynamics
- 5.1. Introduction
- 5.2. DRO Analysis
- 5.2.1. Drivers
- 5.2.2. Restraints
- 5.2.3. Opportunities
- Chapter 6. Global Retinal Biologics Market, By Drug Class
- 6.1. Introduction
- 6.2. TNF-α Inhibitor
- 6.3. VEGF-A Antagonist
- Chapter 7. Global Retinal Biologics Market, By Retinal Disorder Type
- 7.1. Introduction
- 7.2. Age-related Macular Degeneration (AMD)
- 7.3. Diabetic Retinopathy (DR)
- 7.4. Diabetic Macular Edema (DME)
- 7.5. Macular Hole
- 7.6. Uveitis
- 7.7. Others
- Chapter 8. Global Retinal Biologics Market, By Distribution Channel
- 8.1. Introduction
- 8.2. Hospitals
- 8.3. Retail Pharmacies
- 8.4. Specialty Ophthalmology Clinics
- Chapter 9. Global Retinal Biologics Market, By Region
- 9.1. Introduction
- 9.2. North America
- 9.2.1. Introduction
- 9.2.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.2.3. Market Size and Forecast, By Country, 2020 - 2028
- 9.2.4. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.2.5. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.2.6. Market Size and Forecast, By Distribution Channel, 2020 – 2028
- 9.2.7. US
- 9.2.7.1. Introduction
- 9.2.7.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.2.7.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.2.7.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.2.7.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.2.8. Canada
- 9.2.8.1. Introduction
- 9.2.8.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.2.8.4. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.2.8.5. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.2.8.6. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.3.3. Market Size and Forecast, By Country, 2020 - 2028
- 9.3.4. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.3.5. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.3.6. Market Size and Forecast, By Distribution Channel, 2020 – 2028
- 9.3.7. Germany
- 9.3.7.1. Introduction
- 9.3.7.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.3.7.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.3.7.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.3.7.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.3.8. France
- 9.3.8.1. Introduction
- 9.3.8.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.3.8.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.3.8.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.3.8.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.3.9. UK
- 9.3.9.1. Introduction
- 9.3.9.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.3.9.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.3.9.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.3.9.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.3.10. Italy
- 9.3.10.1. Introduction
- 9.3.10.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.3.10.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.3.10.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.3.10.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.3.11. Rest of Europe
- 9.3.11.1. Introduction
- 9.3.11.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.3.11.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.3.11.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.3.11.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.4. Asia-Pacific
- 9.4.1. Introduction
- 9.4.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.4.3. Market Size and Forecast, By Country, 2020 - 2028
- 9.4.4. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.4.5. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.4.7. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.4.8. China
- 9.4.8.1. Introduction
- 9.4.8.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.4.8.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.4.8.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.4.8.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.4.9. India
- 9.4.9.1. Introduction
- 9.4.9.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.4.9.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.4.9.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.4.9.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.4.10. Japan
- 9.4.10.1. Introduction
- 9.4.10.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.4.10.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.4.10.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.4.10.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.4.11. South Korea
- 9.4.11.1. Introduction
- 9.4.11.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.4.11.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.4.11.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.4.11.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.4.12. Rest of Asia-Pacific
- 9.4.11.1. Introduction
- 9.4.12.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.4.12.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.4.12.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.4.12.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.5. Rest of The World (RoW)
- 9.5.1. Introduction
- 9.5.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.5.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.5.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.5.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.5.6. Market Size and Forecast, By Region, 2020 - 2028
- 9.5.7. South America
- 9.5.7.1. Introduction
- 9.5.7.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.5.7.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.5.7.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.5.7.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- 9.5.8. Middle East & Africa
- 9.5.8.1. Introduction
- 9.5.8.2. Driving Factors, Opportunity Analyzed and Key Trends
- 9.5.8.3. Market Size and Forecast, By Drug Class, 2020 - 2028
- 9.5.8.4. Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028
- 9.5.8.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
- Chapter 10. Competitive Landscape
- 10.1. Introduction
- 10.2. Vendor Share Analysis, 2020/Key Players Positioning 2020
- Chapter 11. Company Profiles
- 11.1. Novartis AG
- 11.1.1. Business Overview
- 11.1.2. Financial Analysis
- 11.1.3. Product Portfolio
- 11.1.4. Recent Development and Strategies Adopted
- 11.1.5. SWOT Analysis
- 11.2. F. Hoffmann La Roche Ltd
- 11.2.1. Business Overview
- 11.2.2. Financial Analysis
- 11.2.3. Product Portfolio
- 11.2.4. Recent Development and Strategies Adopted
- 11.2.5. SWOT Analysis
- 11.3. AbbVie Inc.
- 11.3.1. Business Overview
- 11.3.2. Financial Analysis
- 11.3.3. Product Portfolio
- 11.3.4. Recent Development and Strategies Adopted
- 11.3.5. SWOT Analysis
- 11.4. MeiraGTx Limited
- 11.4.1. Business Overview
- 11.4.2. Financial Analysis
- 11.4.3. Product Portfolio
- 11.4.4. Recent Development and Strategies Adopted
- 11.4.5. SWOT Analysis
- 11.5. OncoGene
- 11.5.1. Business Overview
- 11.5.2. Financial Analysis
- 11.5.3. Product Portfolio
- 11.5.4. Recent Development and Strategies Adopted
- 11.5.5. SWOT Analysis
- 11.6. Johnson & Johnson
- 11.6.1. Business Overview
- 11.6.2. Financial Analysis
- 11.6.3. Product Portfolio
- 11.6.4. Recent Development and Strategies Adopted
- 11.6.5. SWOT Analysis
- 11.7. Allergan
- 11.7.1. Business Overview
- 11.7.2. Financial Analysis
- 11.7.3. Product Portfolio
- 11.7.4. Recent Development and Strategies Adopted
- 11.7.5. SWOT Analysis
- 11.8. Bristol-Myers Squibb Company
- 11.8.1. Business Overview
- 11.8.2. Financial Analysis
- 11.8.3. Product Portfolio
- 11.8.4. Recent Development and Strategies Adopted
- 11.8.5. SWOT Analysis
- 11.9. Regeneron
- 11.9.1. Business Overview
- 11.9.2. Financial Analysis
- 11.9.3. Product Portfolio
- 11.9.4. Recent Development and Strategies Adopted
- 11.9.5. SWOT Analysis
- 11.10. Oxurion NV
- 11.10.1. Business Overview
- 11.10.2. Financial Analysis
- 11.10.3. Product Portfolio
- 11.9.4. Recent Development and Strategies Adopted
- 11.9.5. SWOT Analysis
- Chapter 12. Key Takeaways
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook